These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29146795)

  • 41. Antibody-dependent enhancement in dengue virus infections.
    Burke DS; Kliks S
    J Infect Dis; 2006 Feb; 193(4):601-3; author reply 603-4. PubMed ID: 16425141
    [No Abstract]   [Full Text] [Related]  

  • 42. Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model.
    Konishi E; Miyagawa Y
    Microbes Infect; 2011 Nov; 13(12-13):1091-8. PubMed ID: 21763777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate.
    McArthur MA; Edelman R
    J Infect Dis; 2015 Sep; 212(5):681-3. PubMed ID: 25801651
    [No Abstract]   [Full Text] [Related]  

  • 44. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
    Lee JS; Lourenço J; Gupta S; Farlow A
    Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-dependent enhancement of severe dengue disease in humans.
    Katzelnick LC; Gresh L; Halloran ME; Mercado JC; Kuan G; Gordon A; Balmaseda A; Harris E
    Science; 2017 Nov; 358(6365):929-932. PubMed ID: 29097492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
    Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
    Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of dengue DNA vaccines.
    Danko JR; Beckett CG; Porter KR
    Vaccine; 2011 Sep; 29(42):7261-6. PubMed ID: 21777640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tropical diseases. Dengue vaccine trial poses public health quandary.
    Normile D
    Science; 2014 Jul; 345(6195):367-8. PubMed ID: 25061184
    [No Abstract]   [Full Text] [Related]  

  • 50. Mosquito control might not bolster imperfect dengue vaccines.
    Paul R; Sousa C; Sakuntabhai A; Devine G
    Lancet; 2014 Nov; 384(9956):1747-8. PubMed ID: 25455246
    [No Abstract]   [Full Text] [Related]  

  • 51. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pathophysiological mechanisms of dengue fever: critical review of current concepts].
    Deparis X; Maréchal V; Matheus S
    Med Trop (Mars); 2009 Aug; 69(4):351-7. PubMed ID: 19725385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial: the challenge of dengue vaccine development and introduction.
    Deen JL
    Trop Med Int Health; 2004 Jan; 9(1):1-3. PubMed ID: 14728601
    [No Abstract]   [Full Text] [Related]  

  • 55. Dengue vaccines: closer but not there yet.
    Galler R; Bonaldo MC; Alves AM
    Mem Inst Oswaldo Cruz; 2011 Dec; 106(8):905-6. PubMed ID: 22241108
    [No Abstract]   [Full Text] [Related]  

  • 56. Breaking the symmetry: immune enhancement increases persistence of dengue viruses in the presence of asymmetric transmission rates.
    Mier-y-Teran-Romero L; Schwartz IB; Cummings DA
    J Theor Biol; 2013 Sep; 332():203-10. PubMed ID: 23665358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Research progress in the structure and function of dengue virus non-structural 1 protein].
    Chen Y; Ren RW; Liu JW
    Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Sun J; Li M; Wang Y; Hao P; Jin X
    Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.